The first patient has been dosed in the P-I study evaluating the safety, tolerability, PK, and preliminary efficacy profile of HMPL-415 as monotx. in patients with advanced malignant solid tumors
Additionally, ~80 patients are expected to be enrolled in the study incl. patients as part of the dose escalation stage, and further patients at RP2D
HMPL-415, a novel, highly potent, and selective allosteric inhibitor that targets protein tyrosine phosphatase-2 containing SHP2. This protein modulates various cell signaling events that control cell migration, differentiation, oncogenic transformation, transcription, cell growth, and metabolism
Ref: Globenewswire | Image: HUTCHMED
Related News:- Takeda and HUTCHMED Reports P-III Study (FRESCO2) Results of Fruquintinib in the P-III Study (FRESCO-2) for Metastatic Colorectal Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com